Subscribe or Manage Preferences
“It’s not just about the drugs” is a common theme, and one that I have personally used often in discussions with payers and employers over the past 6 years. However, as value-based payment reform ramps up, it is equally important [ Read More ]
The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) has placed even more emphasis on the common coding phrase, “If it isn’t documented, it can’t be reported.” The increased specificity of the new code set is about more than [ Read More ]
The way we treat patients with cancer is changing, as providers use patient-centered care and targeted therapies, and as oral oncolytics become increasingly prevalent in the marketplace. These innovative, self-administered therapies offer better quality of life for patients who are [ Read More ]
Although it may have taken 17 years to repeal the sustainable growth rate formula, according to Lemeneh Tefera, MD, MSc, Medical Officer at the Center for Clinical Standards and Quality in the Centers for Medicare & Medicaid Services (CMS), it [ Read More ]
This is the third article in our series on the US Pharmacopeia Convention (USP)’s “General Chapter 800 Hazardous Drugs” (USP 800) regulations regarding handling hazardous drugs. Our goal is to provide information primarily on the unreimbursed compliance efforts of one [ Read More ]
The use of novel agents in multiple myeloma has led experts to question whether autologous stem-cell transplant (ASCT) is warranted upfront, or whether it can be used as effectively after patients relapse. The results of the IFM/DFCI-2009 trial, which were [ Read More ]
Patients with previously treated metastatic urothelial cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab [ Read More ]
Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for [ Read More ]
Experience at a high-volume cancer center suggests that nonstereotactic body radiotherapy external beam reirradiation of the pelvis for cancer recurrence or for a second genitourinary malignancy is safe in patients with advanced cancer, and can achieve excellent and durable palliation [ Read More ]
Patients with multiple myeloma are making significant lifestyle trade-offs to manage the cost of healthcare, according to findings from the Cancer Experience Registry presented at ASH 2015. Joanne S. Buzaglo, PhD, Senior Vice President, Research and Training, Cancer Support Community, [ Read More ]
As we move into another year, it is important now more than ever for medical practices to ensure that they have a robust Health Insurance Portability and Accountability Act (HIPAA) compliance program in place. In 2009, the Office for Civil [ Read More ]
Last year, I presented at the 2015 American Association of Managed Care Nurses (AAMCN) preconference on “Managed Care Nurses and the Clinical and Economic Impact of Nutritional Interventions in Patient Outcomes.” The focus of the conference was disease-related malnutrition. In [ Read More ]
The following clinical trials represent a selection of key clinical trials that are currently recruiting patients with colorectal cancer for inclusion in investigations of new therapies and new regimens of available therapies for patients with colorectal cancer. Each clinical trial [ Read More ]
This detailed article of codes related to colorectal cancer is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with colorectal cancer. [ Read More ]
Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure.1,2 According to the American Cancer Society, more than 26,800 new cases of multiple myeloma were diagnosed in 2015, [ Read More ]